Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biopharmaceutical company that focuses on developing and acquiring technologies that aid in the discovery and development of medicines. The company operates in a competitive landscape with peers like Neurocrine Biosciences, Incyte Corporation, Alkermes plc, Myriad Genetics, and United Therapeutics Corporation. These companies are also involved in the pharmaceutical and biotechnology sectors, each with its own focus and strengths.
In analyzing Ligand's financial performance, the Return on Invested Capital (ROIC) is a critical metric. Ligand's ROIC is -3.48%, which is below its Weighted Average Cost of Capital (WACC) of 7.27%. This negative ROIC indicates that Ligand is not generating sufficient returns to cover its cost of capital, suggesting inefficiencies in its investment strategies.
Comparatively, Neurocrine Biosciences has a ROIC of 9.78% and a WACC of 5.50%, resulting in a ROIC to WACC ratio of 1.78. This positive ratio indicates that Neurocrine is effectively generating returns above its cost of capital. Similarly, Incyte Corporation and United Therapeutics Corporation also show strong financial performance with ROIC to WACC ratios of 2.52 and 2.31, respectively.
Alkermes plc stands out with the highest ROIC to WACC ratio of 3.00, with a ROIC of 18.03% and a WACC of 6.00%. This indicates that Alkermes is generating returns significantly above its cost of capital, showcasing efficient capital utilization and strong financial performance. In contrast, Myriad Genetics has a negative ROIC of -71.95%, which is far below its WACC of 10.67%, resulting in a ROIC to WACC ratio of -6.74, indicating substantial inefficiencies.
Overall, while Ligand Pharmaceuticals is currently underperforming in terms of ROIC relative to its WACC, the peer comparison highlights the varying levels of capital efficiency among its competitors. Alkermes plc, in particular, demonstrates the most efficient use of capital, setting a benchmark for financial performance in the industry.
